Università di Torino | Italy
When metastatic cancers are challenged with targeted agents, almost invariably a subset of cells insensitive to the drug emerges. As a result targeted therapies are often only transiently effective in patients. How can we overcome the near-certainty of disease recurrence following treatment with targeted agents? Addressing this question means considering as a target not 'only' individual oncogenes but also the evolving nature of human tumors.
Keywords: Colorectal cancer / genomics / resistance to therapy / liquid biopsies / cancer models